EU approves aflibercept for myopic CNV

The European Commission approved aflibercept (Eyela) for a fifth indication, visual impairment due to myopic choroidal neovascularization (CNV).

The anti-VEGF drug is already approved for wet AMD, diabetic macular edema, diabetic retinopathy and for macular edema secondary to retinal vein occlusion (branch RVO or central RVO). It was previously approved in Japan for myopic CNV in September 2014.

Bayer, which has exclusive marketing rights outside the United States, plans for an immediate introduction to the European market starting with Germany.